Nyxoah announces appointment of new CEO Olivier Taelman
Nyxoah S.A., a healthtech company developing neurostimulation-based therapeutic solutions for sleep related disorders, announced today the appointment of Olivier Taelman as new CEO of Nyxoah, following the resignation of Enrique Vega for personal reasons. Nyxoah’s founder and chairman Robert Taub will continue to serve as executive chairman focused on business development and financing.
Olivier Taelman joined Nyxoah in July 2019 as Chief Operating and Commercial Officer with more than 20 years experience in commercial healthcare and general management roles. He spent 15 years within the field of neuromodulation including at Medtronic, Stryker and neuromodulation company Nevro where he was responsible for building the European business during the successful NASDAQ IPO. He holds an Executive MBA from Wharton and graduated in Biology from the University of Hasselt.
The board and the shareholders of Nyxoah would like to thank Enrique Vega for his contributions to the company including bringing Nyxoah from development stage to CE mark of its Genio® system.
About Obstructive Sleep Apnea (OSA) and the Genio® system
OSA is the world’s most common sleep disordered breathing condition, affecting almost one billion people globally1. It makes a person stop breathing during sleep, while the airway repeatedly becomes partially (hypopnea) or totally (apnea) blocked, limiting the amount of air that reaches the lungs. OSA is a chronic condition that is associated with increased mortality risk and comorbidities, including cardiovascular diseases, type 2 diabetes, obesity, depression and stroke. The current standard of care consists of Continuous Positive Airway Pressure (CPAP) therapy, a treatment whereby air is pushed into the upper airway to keep it open.
The Genio® system is the world’s first and only, battery-free, leadless and minimally invasive implanted neurostimulator designed to keep the upper airway open during sleep for certain people with OSA by bilateral stimulation of the hypoglossal nerve.
Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services for sleep disordered breathing conditions. Nyxoah’s lead solution is the Genio® system, a validated, user-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk2 and comorbidities including cardiovascular diseases, depression and stroke.
Following successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE Mark in March 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio® system.
For more information, please visit www.nyxoah.com.
Caution – CE marked since 2019. Investigational device in the United States. Limited by United States federal law to investigational use.
1.Benjafield, Adam V et al. Estimation of the global prevalence and burden of obstructive sleep apnea: a literature-based analysis. Lancet Respir Med 2019 Published Online July 9, 2019 http://dx.doi.org/10.1016/S2213-2600(19)30198-5
2 Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen-Year Follow-up of the Wisconsin Sleep Cohort, Sleep. 2008 Aug 1; 31(8): 1071–1078.